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Enzyme Inhibitor May Offer Dual Protection against
Brain Disease
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Chromosomes are extraordinarily long,
wiggly strands, making up more than two
meters of DNA in each human cell, and
given the 50 trillion or so cells in the
human body, we have enough DNA in
each of us to go from here to the sun and
back more than 300 times. To wrangle
chromosomes into nuclei only ten to 20
microns wide, these molecules are wound
tightly around proteins known as histones,
compacting them by a factor of 10,000
during cell division.
By controlling access to genetic materi-
al, histones are more than just spools, but
caretakers as well. Now, Robert Lahue
and his colleagues find enzymes that
tamper with these guardians can warp
the DNA wrapped around them, trigger-
ing mutations that are the cause of at least
17 inherited neurological human disor-
ders, including Huntington’s disease.
There is a silver lining to this discovery:
interfering with these enzymes could help
treat these diseases in high risk individuals,
and some drugs that do just that are
already under investigation.
The mutations in question are trinucle-
otide repeat expansions, where three-
nucleotide-long pieces of gene code such
as cytosine-adenine-guanine (CAG) get
repeatedly inserted into genes. Once these
repeats pile up or ‘‘expand’’ past a certain
threshold number within genes—say, 30
to 40 uninterrupted repeats in humans—
genetic activity can get disrupted, with
potentially tragic results.
To find out the mysterious root of these
mutations, Lahue and his colleagues started
with yeast that already possessed stretches
of 20 cytosine-thymine-guanine (CTG)
repeats. The more such repeats they
accumulate, the more resistant they prove
to the toxin canavanine. The researchers
dosed yeast cells with mutagens, causing
9,000 random mutations in approximately
half of yeast’s non-essential genes. Treat-
ment with canavanine then revealed 11
mutant genes that caused persistent vulner-
ability to the toxin, suggesting they might
normally help generate repeats.
Three of these genes were linked with
enzymes known as histone deacetylases
(HDACs),which removeacetylgroupsfrom
histones. Knocking out any one of these
genes reduced trinucleotide repeat expan-
sion rates by 50 to 90 percent, confirming
their normal ability to help mutate DNA.
To see what might happen in human
cells, the scientists exposed lab-grown
astrocytes—human nervous system cells
that are among the targets of Huntington’s
disease—to an HDAC inhibitor known as
4b. This suppressed trinucleotide repeat
expansion rates by about 75 percent.
Using RNA interference to knock down
the enzyme HDAC3 in these cells had
much the same effect. On the other hand,
knocking down enzymes known as histone
acetyltransferases that add acetyl groups to
histones, the opposite of HDACs, in-
creased expansion frequency.
Lahue and his team’s experiments
suggest that although there are at least
14 different types of HDACs in human
cells, only one or a few seem to affect
trinucleotide repeat expansions, such as
HDAC3. These might not only generate
the inherited cause of Huntington’s and
other diseases—the trinucleotide re-
peats—but might further exacerbate these
problems during patients’ lifetimes by
causing more repeats. Lahue said future
work will focus on why HDAC3 specifi-
cally causes expansions.
The researchers suggest HDACs can
inadvertently promote expansions by pro-
longing the lifetimes of proteins normally
involved in DNA repair. Experiments with
yeast mutants revealed the DNA-cleaving
nuclease Sae2, which recent studies suggest
is stabilized by histone deacetylation, ap-
pears to be a target of HDACs, promoting
expansions by working together with the
nuclease Mre11.
The HDAC inhibitor the researchers
used, 4b, is already being tested as a
treatment in Huntington’s disease. The
protein huntingtin apparently binds to
Argonaute proteins, which are responsible
for micro-RNA-mediated gene silencing;
HDAC inhibitors affect gene transcription,
potentially alleviating the abnormal gene
silencing triggered by the mutant hunting-
tin of Huntington’s disease. Intriguingly, it
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Combined actions of HDACs and DNA
repair outweigh HATs, resulting in ex-
pansions (a). But perturbing this situa-
tion, for example, adding an HDAC
inhibitor (b), changes the outcome (sta-
bilizing trinucleotide repeats).
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effects of the disease, butalso suppresses the
mutations that contribute to the disorder.
Lahue hopes to work with other labs to see
if blocking HDAC3 in mice helps relieve
trinucleotide repeat expansions in the
brain. He adds that specific HDAC3
inhibitors might be developed as muta-
tion-blocking therapies for additional hu-
man triplet repeat expansion diseases.
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